BACKGROUND: Active Surveillance (AS) is recommended for the treatment of localised prostate cancer; however this option may be under-used, at least in part because of expectations of psychological adverse events in those offered or accepting AS.
OBJECTIVE: (1) Determine the impact on psychological wellbeing when treated with AS (non-comparative studies). (2) Compare AS with active treatments for the impact on psychological wellbeing (comparative studies).
METHOD: We used the PRISMA guidelines and searched Medline, PsychInfo, EMBASE, CINHAL, Web of Science, Cochrane Library and Scopus for articles published January 2000-2014. Eligible studies reported original quantitative data on any measures of psychological wellbeing.
RESULTS: We identified 34 eligible articles (n=12,497 individuals); 24 observational, eight RCTs, and two other interventional studies. Studies came from North America (16), Europe (14) Australia (3) and North America/Europe (1). A minority (5/34) were rated as high quality. Most (26/34) used validated instruments, whilst a substantial minority (14/34) used watchful waiting or no active treatment rather than Active Surveillance. There was modest evidence of no adverse impact on psychological wellbeing associated with Active Surveillance; and no differences in psychological wellbeing compared to active treatments.
CONCLUSION: Patients can be informed that Active Surveillance involves no greater threat to their psychological wellbeing as part of the informed consent process, and clinicians need not limit access to Active Surveillance based on an expectation of adverse impacts on psychological wellbeing.
Carter G, Clover K, Britton B, Mitchell AJ, White M, McLeod N, Denham J, Lambert SD. Are you the author?
Centre for Translational Neuroscience and Mental Health, School of Medical Practice and Population Health, Faculty of Health, University of Newcastle, NSW, Australia; Psycho-Oncology Service, Calvary Mater Newcastle, School of Psychology, Faculty of Science and Information Technology, Centre for Translational Neuroscience & Mental Health Research, University of Newcastle, Australia; Depart of Cancer & Molecular Medicine, Leicester Royal Infirmary & University of Leicester, Leicester LE5 1WW, United Kingdom; Consultant Urologist, New Lambton, Newcastle, NSW, Australia; John Hunter Hospital, New Lambton, Newcastle, NSW, Australia; Faculty of Health and Medicine, Prostate Cancer Trials Group, School of Medicine and Public Health, University of Newcastle, NSW, Australia; Ingram School of Nursing, McGill University, Canada.
Reference: Cancer Treat Rev. 2015 Jan;41(1):46-60.